Alvotech to Report Financial Results for the First Nine Months of 2024 on November 13, 2024, and Host Conference Call on November 14, 2024, at 8:00 am ET
30 Outubro 2024 - 9:30AM
Alvotech (NASDAQ: ALVO), a global biotech company specialized in
the development and manufacture of biosimilar medicines for
patients worldwide, will release financial results for first nine
months of the year ended September 30, 2024, after U.S. markets
close on Wednesday, November 13, 2024, and will conduct a
conference call with analysts to present the financial results and
recent business highlights on Thursday November 14, 2024, at 8:00
am ET (13:00 GMT).
Live audio of the conference call will also be webcast and
available to members of the news media, investors, and the general
public. Access information is posted on Alvotech’s investor portal
https://investors.alvotech.com. A direct link to the event, with a
link to the webcast and separate call-in information for analysts
can be found at
https://investors.alvotech.com/events/event-details/q3-2024-earnings.
The webcast will also be archived and available for replay for 90
days after the event.
About AlvotechAlvotech is a biotech company,
founded by Robert Wessman, focused solely on the development and
manufacture of biosimilar medicines for patients worldwide.
Alvotech seeks to be a global leader in the biosimilar space by
delivering high quality, cost-effective products, and services,
enabled by a fully integrated approach and broad in-house
capabilities. Alvotech has launched two biosimilars. The current
development pipeline includes nine disclosed biosimilar candidates
aimed at treating autoimmune disorders, eye disorders,
osteoporosis, respiratory disease, and cancer. Alvotech has formed
a network of strategic commercial partnerships to provide global
reach and leverage local expertise in markets that include the
United States, Europe, Japan, China, and other Asian countries and
large parts of South America, Africa and the Middle East.
Alvotech’s commercial partners include Teva Pharmaceuticals, a US
affiliate of Teva Pharmaceutical Industries Ltd. (US), STADA
Arzneimittel AG (EU), Fuji Pharma Co., Ltd (Japan), Advanz Pharma
(EEA, UK, Switzerland, Canada, Australia and New Zealand), Dr.
Reddy’s (EEA, UK and US), Biogaran (France), Cipla/Cipla Gulf/Cipla
Med Pro (Australia, New Zealand, South Africa/Africa), JAMP Pharma
Corporation (Canada), Yangtze River Pharmaceutical (Group) Co.,
Ltd. (China), DKSH (Taiwan, Hong Kong, Cambodia, Malaysia,
Singapore, Indonesia, India, Bangladesh and Pakistan), YAS Holding
LLC (Middle East and North Africa), Abdi Ibrahim (Turkey), Kamada
Ltd. (Israel), Mega Labs, Stein, Libbs, Tuteur and Saval (Latin
America) and Lotus Pharmaceuticals Co., Ltd. (Thailand, Vietnam,
Philippines, and South Korea). Each commercial partnership covers a
unique set of product(s) and territories. Except as specifically
set forth therein, Alvotech disclaims responsibility for the
content of periodic filings, disclosures and other reports made
available by its partners. For more information, please visit
www.alvotech.com. None of the information on the Alvotech website
shall be deemed part of this press release.
ALVOTECH INVESTOR RELATIONS AND GLOBAL
COMMUNICATIONSBenedikt Stefansson,
VPalvotech.ir@alvotech.com
Please visit our investor portal, and our website or follow us
on social media on LinkedIn, Facebook, Instagram, X and
YouTube.
Alvontech (NASDAQ:ALVO)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Alvontech (NASDAQ:ALVO)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024